SAN FRANCISCO – Sequenta, Inc., and its collaborators will share important data at the American Society of Hematology (ASH) annual meeting showing the sensitivity of the company’s LymphoSIGHT™ platform for the detection of minimal residual disease (MRD).

The company and multiple investigators have demonstrated that the LymphoSIGHT™ technology can measure MRD in samples in which the disease was undetectable using flow cytometry and/or polymerase chain reaction (PCR).
Sequenta will make three oral and six poster presentations at ASH, scheduled for Dec. 8-11, 2012, at the Georgia World Congress Center in Atlanta.

“These presentations underscore the broad adoption of the LymphoSIGHT™ platform by the clinical research community and provide the vital clinical validation of our clinical products that will be available early next year,” said Tom Willis, CEO of Sequenta. “The presentations highlight both the technical power of the next-generation sequencing approach, as well as the breadth of its applicability to a full range of blood cancers.”

The 54th annual ASH meeting brings together the leaders in hematology, including nearly 300 pharmaceutical companies, medical suppliers, and clinical diagnostic and research-based companies to share the latest research and technology advancements in the field.

Sequenta is a venture backed startup dedicated to improving patient care in diseases mediated by immune cells through measurements of lymphocyte diversity. It is commercializing its LymphoSIGHT™ platform for clinical use in minimal residual disease while continuing to validate the use of its technology in a diverse set of diseases. For more information, go to www.sequentainc.com.